Masloh, S.; Chevrel, A.; Culot, M.; Perrocheau, A.; Kalia, Y.N.; Frehel, S.; Gaussin, R.; Gosselet, F.; Huet, S.; Zeisser Labouebe, M.;
et al. Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model. Pharmaceutics 2024, 16, 116.
https://doi.org/10.3390/pharmaceutics16010116
AMA Style
Masloh S, Chevrel A, Culot M, Perrocheau A, Kalia YN, Frehel S, Gaussin R, Gosselet F, Huet S, Zeisser Labouebe M,
et al. Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model. Pharmaceutics. 2024; 16(1):116.
https://doi.org/10.3390/pharmaceutics16010116
Chicago/Turabian Style
Masloh, Solene, Anne Chevrel, Maxime Culot, Anaëlle Perrocheau, Yogeshvar N. Kalia, Samuel Frehel, Rémi Gaussin, Fabien Gosselet, Simon Huet, Magali Zeisser Labouebe,
and et al. 2024. "Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model" Pharmaceutics 16, no. 1: 116.
https://doi.org/10.3390/pharmaceutics16010116
APA Style
Masloh, S., Chevrel, A., Culot, M., Perrocheau, A., Kalia, Y. N., Frehel, S., Gaussin, R., Gosselet, F., Huet, S., Zeisser Labouebe, M., & Scapozza, L.
(2024). Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model. Pharmaceutics, 16(1), 116.
https://doi.org/10.3390/pharmaceutics16010116
